GUIDED THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
GTHPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
The consolidated financial statements included in Item 8 of this report are filed as part of this report.
The exhibits listed below are filed as part hereof, or incorporated by reference into, this Report. All documents referenced below were filed pursuant to the Securities and Exchange Act of 1934 by Guided Therapeutics, Inc. (f/k/a SpectRx, Inc.), file number 0-22179, unless otherwise indicated.
| Exhibit Number | Exhibit Description |
| 1.1 | Form of Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the annual report on Form 10-K filed March 30, 2022) |
| 3.1 | Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016) |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012) |
| 3.3 | Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018) |
| 3.4 | Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021) |
| 3.6 | Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021) |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021) |
| 3.8 | Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022) |
| 3.9 | Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022) |
| 4.1 | Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the amended registration statement on Form S-1/A (No. 333-22429) filed April 24, 1997) |
| 4.2 | Secured Promissory Note, dated September 10, 2014 (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed September 10, 2014) |
| 4.3 | Amendment #1 to Secured Promissory Note, dated March 10, 2015 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed March 19, 2015) |
| 4.4 | Amendment #2 to Secured Promissory Note, dated May 4, 2015 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed May 7, 2015) |
| 4.5 | Amendment #3 to Secured Promissory Note, dated June 1, 2015 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed June 5, 2015) |
| 4.6 | Amendment #4 to Secured Promissory Note, dated June 16, 2015 (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K filed June 30, 2015) |
| 4.7 | Amendment #5 to Secured Promissory Note, dated June 29, 2015 (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K filed June 30, 2015) |
| 4.8 | Amendment #6 to Secured Promissory Note, dated January 20, 2016 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed February 16, 2016) |
| 4.9 | Amendment #7 to Secured Promissory Note, dated February 11, 2016 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K filed February 16, 2016) |
| 4.10 | Amendment #8 to Secured Promissory Note, dated March 7, 2016 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed March 7, 2016) |
| 4.11 | Senior Secured Convertible Note, dated February 12, 2016 (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed February 12, 2016) |
| 4.12 | Form of Exchange Note (GPB) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed December 7, 2016) |
| 4.13 | 10% OID Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed December 30, 2016) |
| 4.14 | Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed February 16, 2017) |
| 4.15 | Form of Warrant (Standard Form) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed September 14, 2010) |
| 4.16 | Form of Warrant (InterScan) (incorporated by reference to Exhibit 4.13 to the annual report on Form 10-K for the year ended December 31, 2013, filed March 27, 2014) |
| 4.17 | Form of Warrant (November 2011 Private Placement) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K/A, filed November 28, 2011) |
| 4.18 | Form of Warrant (Series B-Tranche A) (incorporated by reference to Exhibit 10.2 to amendment no. 1 to the current report on Form 8-K, filed May 23, 2013) |
| 4.19 | Form of Warrant (Series B-Tranche B) (incorporated by reference to Exhibit 10.3 to amendment no. 1 to the current report on Form 8-K, filed May 23, 2013) |
| 4.20 | Form of Warrant (Regulation S) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed September 8, 2014) |
| 4.21 | Form of Warrant (2014 Public Offering Placement Agent) (incorporated by reference to Exhibit 4.2 to the current report on Form 8-K filed December 4, 2014) |
| 4.22 | Form of Warrant (2014 Public Offering Warrant Exchanges) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed June 30, 2015) |
| 4.23 | Form of Warrant (Series C) (incorporated by reference to Exhibit 4.3 to the current report on Form 8-K filed June 30, 2015) |
| 4.24 | Form of Warrant (Senior Secured Convertible Note) (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K filed February 12, 2016) |
| 4.25 | Form of Warrant (Series B-Tranche B Exchanges; GPB Exchange) (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K filed June 14, 2016) |
| 4.26 | Common Stock Purchase Warrant (Convertible Promissory Note) (incorporated by reference to Exhibit 4.2 to the current report on Form 8-K filed February 16, 2017) |
| 4.27 | Senior Secured Convertible Note, dated December 17, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.28 | Common Stock Warrant, dated December 17, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.29 | Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.30 | Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.31 | Form of 12% debenture (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.32 | Form of Warrant (Exchange Agreements) (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.33 | Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 4.34 | Convertible Promissory Note with Auctus, dated March 31, 2020 (incorporated by reference to Exhibit 4.34 to the annual report on Form 10-K filed April 5, 2021) |
| 4.35 | Form of Warrant (Auctus Note), dated March 31, 2020 (incorporated by reference to Exhibit 4.35 to the annual report on Form 10-K filed April 5, 2021) |
| 4.36 | Form of Warrant (Series D Preferred Stock) (incorporated by reference to Exhibit 4.36 to the annual report on Form 10-K filed April 5, 2021) |
| 4.37 | Form of Warrant (Series D Preferred Stock) (incorporated by reference to Exhibit 4.37 to the annual report on Form 10-K filed April 5, 2021) |
| 4.38 | Form of Warrant (Ironstone Capital), dated April 23, 2020 (incorporated by reference to Exhibit 4.38 to the annual report on Form 10-K filed April 5, 2021) |
| 4.39 | Form of Warrant (Auctus Note), dated May 22, 2020 (incorporated by reference to Exhibit 4.39 to the annual report on Form 10-K filed April 5, 2021) |
| 4.40 | Form of Warrant (Credential Qtrade Securities Inc. ITF Reve Royalty Income Growth, dated as of June 23, 2020) (incorporated by reference to Exhibit 4.40 to the annual report on Form 10-K filed April 5, 2021) |
| 4.41 | Form of Warrant (James Clavijo), dated June 23, 2020 (incorporated by reference to Exhibit 4.41 to the annual report on Form 10-K filed April 5, 2021) |
| 4.42 | Form of Warrant (Manju Venugopal), dated August 10, 2020 (incorporated by reference to Exhibit 4.42 to the annual report on Form 10-K filed April 5, 2021) |
| 4.43 | Note Payable Agreement with Gene Cartwright, dated February 19, 2021 (incorporated by reference to Exhibit 4.43 to the annual report on Form 10-K filed April 5, 2021) |
| 4.44 | Note Payable Agreement with Mark Faupel, dated February 19, 2021 (incorporated by reference to Exhibit 4.44 to the annual report on Form 10-K filed April 5, 2021) |
| 4.45 | Form of Warrant (Aspen Capital), dated June 23, 2020 (incorporated by reference to Exhibit 4.45 to the annual report on Form 10-K filed April 5, 2021) |
| 4.46 | Form of Common Stock Purchase Warrant (Aspen Capital) dated May 31, 2021 (incorporated by reference to Exhibit 4.46 to the annual report on Form 10-K filed March 30, 2022) |
| 4.47 | Form of Common Stock Purchase Warrant (Iron Stone Capital) dated August 10, 2021 (incorporated by reference to Exhibit 4.47 to the annual report on Form 10-K filed March 30, 2022) |
| 4.48 | Form of Common Stock Purchase Warrant dated November 4, 2021 (incorporated by reference to Exhibit 4.48 to the annual report on Form 10-K filed March 30, 2022) |
| 4.49 | Form of Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on 8-K, filed on September 15, 2022 |
| 4.50 | Form of Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on 8-K, filed on September 15, 2022 |
| 10.1 | 1995 Stock Plan and form of Stock Option Agreement (incorporated by reference to Exhibit 10.2 to the registration statement on Form S-1 (No. 333-22429) filed February 27, 1997) |
| 10.2 | 2005 Amendment to 1995 Stock Plan (incorporated by reference to Appendix 1 to the proxy statement on Schedule 14A, filed May 10, 2005) |
| 10.3 | 2010 Amendment to 1995 Stock Plan (incorporated by reference to Exhibit 10.3 to the registration statement on Form S-8 (File No. 333-178261), filed December 1, 2011) |
| 10.4 | 2012 Amendment to 1995 Stock Plan (incorporated by reference to Annex 1 to the proxy statement on Schedule 14A, filed April 30, 2012) |
| 10.5 | Securities Purchase Agreement (Series C), dated June 29, 2015 (incorporated by reference to Exhibit 10.6 to the current report on Form 8-K filed June 30, 2015) |
| 10.6 | Registration Rights Agreement (Series C), dated June 29, 2015 (incorporated by reference to Exhibit 10.7 to the current report on Form 8-K filed June 30, 2015) |
| 10.7 | Form of Joinder Agreement (Series C) (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed July 13, 2015) |
| 10.8 | Interim Securities Purchase Agreement (Series C), dated September 3, 2015 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed September 3, 2015) |
| 10.9 | Securities Purchase Agreement (Senior Secured Convertible Note), dated February 11, 2016 (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K filed February 12, 2016) |
| 10.10 | Security Agreement (Senior Secured Convertible Note), dated February 11, 2016 (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K filed February 12, 2016) |
| 10.11 | Royalty Agreement, dated September 6, 2016, between the Company and Imhoff and Maloof (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed September 8, 2016) |
| 10.12 | Agreement between Shandong Yaohua Medical Instrument Corporation and Guided Therapeutics, Inc., Confidential, Final 22 January 2017 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed January 26, 2017) |
| 10.13 | Guided Therapeutics-Shenghuo Medical Agreement, 22 Jan 2017 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K filed January 26, 2017) |
| 10.14 | Securities Purchase Agreement, dated as of February 12, 2018, by and between Guided Therapeutics, Inc. and Adar Bays, LLC |
| 10.15 | Securities Purchase Agreement, dated as of February 22, 2018, by and between Guided Therapeutics, Inc. and Power Up (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.16 | Lease Modification, dated as of February 23, 2018, by and between Guided Therapeutics, Inc. and TREA Infill Industrial Atlanta, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.17 | Securities Purchase Agreement, dated as of March 12, 2018, by and between Guided Therapeutics, Inc. and Eagle Equities, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.18 | Securities Purchase Agreement, dated as of May 17, 2018, by and between Guided Therapeutics, Inc. and GHS Investments, Inc (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.19 | Securities Purchase Agreement, dated as of March 20, 2018, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.20 | Securities Purchase Agreement, dated as of April 30, 2018, by and between Guided Therapeutics, Inc. and Power Up (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.21 | Securities Purchase Agreement, dated as of June 7, 2018, by and between Guided Therapeutics, Inc. and Power Up (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.22 | Securities Purchase Agreement, dated as of June 22, 2018, by and between Guided Therapeutics, Inc. and GHS Investments, Inc (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.23 | Securities Purchase Agreement, dated as of July 3, 2018, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.24 | Promissory Note, dated as of August 22, 2018, by and between Guided Therapeutics, Inc. and Mr. Case (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.25 | Exchange Agreements, dated as of August 31, 2018, by and between Guided Therapeutics, Inc. and Series C1 Preferred Stockholders in exchange for Series C2 Preferred Stock. (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed September 6, 2018) |
| 10.26 | Promissory Note, dated as of September 19, 2018, by and between Guided Therapeutics, Inc. and Mr. Gould (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.27 | Exchange Agreement, dated as of September 30, 2018, by and between Guided Therapeutics, Inc. and Dr. Faupel (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.28 | Exchange Agreement, dated as of September 30, 2018, by and between Guided Therapeutics, Inc. and Dr. Cartwright (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.29 | Equity Financing Agreement, dated as of March 1, 2018, by and between Guided Therapeutics, Inc. and GHS Investments, Inc (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.30 | Purchase and Sale Agreement, dated as of February 14, 2019, by and between Guided Therapeutics, Inc. and Everest Business Funding (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.31 | Promissory Note, dated as of February 15, 2019, by and between Guided Therapeutics, Inc. and Mr. Gould (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.32 | Securities Purchase Agreement, dated as of March 29, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.33 | Securities Purchase Agreement, dated as of May 15, 2019, by and between Guided Therapeutics, Inc. and Eagle Equities, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.34 | Securities Purchase Agreement, dated as of May 15, 2019, by and between Guided Therapeutics, Inc. and Adar Bays, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.35 | Loan Agreement, dated as of July 1, 2019, by and between Guided Therapeutics, Inc. and Accilent Capital Management Inc. / Rev Royalty Trust Income and Growth Trust (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.36 | License Agreement Modification, dated as of July 24, 2019, by and between Guided Therapeutics, Inc. and Shandong Medical Instrument Corporation (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.37 | Addendum to the Exchange Agreement, dated as of September 30, 2018, by and between Guided Therapeutics, Inc. and Dr. Faupel (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.38 | Addendum to the Exchange Agreement, dated as of September 30, 2018, by and between Guided Therapeutics, Inc. and Dr. Cartwright (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.39 | Exchange Agreement, dated as of December 5, 2019, by and between Guided Therapeutics, Inc. and Aquarius (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.40 | Securities Purchase Agreement, dated as of December 17, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.41 | Security Agreement, dated December 17, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.42 | Registration Rights Agreement, dated December 17, 2019, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.43 | Form of Securities Purchase Agreement between the Guided Therapeutics, Inc. and investors set forth therein (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.44 | Form of Security Agreement between the Guided Therapeutics, Inc. and investors set forth therein (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.46 | Securities Purchase Agreement (Series D), dated December 30, 2019 (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.47 | Registration Rights Agreement (Series D), dated December 30, 2019 (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.48 | Form of Joinder Agreement (Series D), dated December 30, 2019 (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.49 | Form of Exchange Agreement, dated as of December 30, 2019, by and between Guided Therapeutics, Inc. and Investors (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.50 | Exchange Agreement, dated as of December 30, 2019, by and between Guided Therapeutics, Inc. and K2 (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.51 | Exchange Agreement, dated as of December 30, 2019, by and between Guided Therapeutics, Inc. and Mr. Blumberg (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.52 | Exchange Agreement, dated as of December 30, 2019, by and between Guided Therapeutics, Inc. and Dr. Imhoff (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.53 | Exchange Agreement, dated as of January 6, 2020, by and between Guided Therapeutics, Inc. and Jones Day Law Firm (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.54 | Finder’s Fee Agreement, dated as of January 6, 2020, by and between Guided Therapeutics, Inc. and Iron Stone Capital (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.55 | Promissory Note, dated as of January 15, 2020, by and between Guided Therapeutics, Inc. and IRTH Communications, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.56 | Exchange Agreement, dated as of January 16, 2020, by and between Guided Therapeutics, Inc. and GPB Debt Holdings II, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.57 | Promotional Agreement, dated as of January 22, 2020, by and between Guided Therapeutics, Inc. and Blumberg & Bowles Consulting, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.58 | Securities Purchase Agreement, dated as of March 31, 2020, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 10.59 | 2018 Stock Option Plan of the Registrant (incorporated by reference to Annex B of Definitive Proxy Statement filed October 11, 2018) |
| 10.60 | Finder’s Fee Agreement with JH Darbie, dated as of May 19, 2020 (incorporated by reference to Exhibit 10.59 to the annual report on Form 10-K filed April 5, 2021) |
| 10.61 | Debt for Equity Exchange Agreement with Auctus, dated as of May 22, 2020 (incorporated by reference to Exhibit 10.60 to the annual report on Form 10-K filed April 5, 2021) |
| 10.62 | Securities Purchase Agreement with Auctus, dated as of May 27, 2020 (incorporated by reference to Exhibit 10.61 to the annual report on Form 10-K filed April 5, 2021) |
| 10.63 | Finder’s Fee Agreement with FCMI, dated as of June 11, 2020 (incorporated by reference to Exhibit 10.62 to the annual report on Form 10-K filed April 5, 2021) |
| 10.64 | Exchange Agreement with William Wells, dated as of July 9, 2020 (incorporated by reference to Exhibit 10.63 to the annual report on Form 10-K filed April 5, 2021) |
| 10.65 | Securities Purchase Agreement with PowerUp, dated as of December 24, 2020 (incorporated by reference to Exhibit 10.64 to the annual report on Form 10-K filed April 5, 2021) |
| 10.66 | Securities Purchase Agreement with PowerUp, dated as of February 10, 2021 (incorporated by reference to Exhibit 10.65 to the annual report on Form 10-K filed April 5, 2021) |
| 10.67 | Consulting Agreement with Richard Blumberg, dated as of March 11, 2021 (incorporated by reference to Exhibit 10.66 to the annual report on Form 10-K filed April 5, 2021) |
| 10.68 | Exchange Agreement with Richard Fowler, dated as of March 22, 2021 (incorporated by reference to Exhibit 10.67 to the annual report on Form 10-K filed April 5, 2021) |
| 10.69 | Securities Purchase Agreement for Series E Preferred Stock (incorporated by reference to Exhibit 10.68 to the annual report on Form 10-K filed April 5, 2021) |
| 10.70 | Securities Purchase Agreement (Series F), dated March 31, 2020 (incorporated by reference to Exhibit 10.68 to the annual report on Form 10-K filed April 5, 2021) |
| 10.71 | Exchange Agreement, dated as of June 23, 2020, by and between Guided Therapeutics, Inc. and James Clavijo (incorporated by reference to exhibit 10.61 to the registration statement on Form S-1/A (No. 333-259871) filed February 17, 2022) |
| 10.72 | Agreement between Shandong Yaohua Medical Instrument Corporation and Guided Therapeutics, Inc., Confidential, Final 12 August 2021 (incorporated by reference to Exhibit 2.1 to the current report on Form 8-K filed September 7, 2021) |
| 10.73 | Agreement dated September 30, 2021, by and between Guided Therapeutics, Inc. and Richard P. Blumberg (incorporated by reference to Exhibit 10.73 to the annual report on Form 10-K filed March 30, 2022) |
| 10.74 | Exchange Agreement, dated as of December 10, 2021, by and between Guided Therapeutics, Inc. and John Imhoff, M.D. (incorporated by reference to Exhibit 10.74 to the annual report on Form 10-K filed March 30, 2022) |
| 10.75 | Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and John Gould (incorporated by reference to Exhibit 10.75 to the annual report on Form 10-K filed March 30, 2022) |
| 10.76 | Exchange Agreement, dated as of December 13, 2021, by and between Guided Therapeutics, Inc. and Frederick Grimm (incorporated by reference to Exhibit 10.76 to the annual report on Form 10-K filed March 30, 2022) |
| 10.77 | Exchange Agreement, dated as of December 16, 2021, by and between Guided Therapeutics, Inc. and Richard P. Blumberg, Esq. (incorporated by reference to Exhibit 10.77 to the annual report on Form 10-K filed March 30, 2022) |
| 10.78 | Exchange Agreement, dated as of December 16, 2021, by and between Guided Therapeutics, Inc. and K2 Medical, LLC (incorporated by reference to Exhibit 10.78 to the annual report on Form 10-K filed March 30, 2022) |
| 10.79 | Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and Gene S. Cartwright (incorporated by reference to Exhibit 10.79 to the annual report on Form 10-K filed March 30, 2022) |
| 10.80 | Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and Mark L. Faupel (incorporated by reference to Exhibit 10.80 to the annual report on Form 10-K filed March 30, 2022) |
| 10.81 | Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and Flynn D. Case Living Trust (incorporated by reference to Exhibit 10.81 to the annual report on Form 10-K filed March 30, 2022) |
| 10.82 | Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and GPB Debt Holdings II LLC (incorporated by reference to Exhibit 10.82 to the annual report on Form 10-K filed March 30, 2022) |
| 10.83 | Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and Michael C. James (incorporated by reference to Exhibit 10.83 to the annual report on Form 10-K filed March 30, 2022) |
| 10.84 | Exchange Agreement, dated as of December 30, 2021, by and between Guided Therapeutics, Inc. and Bryan Mamula (incorporated by reference to Exhibit 10.84 to the annual report on Form 10-K filed March 30, 2022) |
| 10.85 | Exchange Agreement, dated as of December 30, 2021, by and between Guided Therapeutics, Inc. and Dolores Maloof (incorporated by reference to Exhibit 10.85 to the annual report on Form 10-K filed March 30, 2022) |
| 10.86 | Promissory Note, dated December 31, 2021, by and between Guided Therapeutics, Inc. and William Wells (incorporated by reference to Exhibit 10.86 to the annual report on Form 10-K filed March 30, 2022) |
| 10.87 | Exchange Agreement dated February 1, 2022, by and between Guided Therapeutics, Inc. and Auctus Fund LLC (incorporated by reference to Exhibit 10.87 to the annual report on Form 10-K filed March 30, 2022) |
| 10.88 | Extension of Auctus Exchange Agreement, dated February 10, 2022 (incorporated by reference to Exhibit 10.88 to the annual report on Form 10-K filed March 30, 2022) |
| 10.89 | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 15, 2022) |
| 10.90 | Exchange Agreement, dated as of September 1, 2022, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on September 15, 2022) |
| 10.91 | Form of Warrants issued to Auctus Fund, LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on September 15, 2022) |
| 10.92 | Form of Warrants issued to Auctus Fund, LLC (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on September 15, 2022) |
| 21.1 | Subsidiaries (incorporated by reference to Exhibit 21.1 to the registration statement on Form S-1 (No. 333-169755) filed October 5, 2010) |
| 23.1* | Consent of UHY LLP |
| 31* | Certification of the Principal Executive Officer and Principal Financial Officer |
| 32.1* | Section 1350 Certifications. |
| 101.1* | Interactive Data File |
*Filed herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.